Oncolytics Biotech Welcomes New Leadership for Future Growth
Oncolytics Biotech Inc. (NASDAQ: ONCY), a notable player in the clinical-stage biotechnology sector focused on immunotherapy for cancer treatment, has proudly appointed Jared Kelly as its new Chief Executive Officer and as a member of its Board of Directors. This significant transition marks a pivotal moment for the organization as it aims to enhance its innovative approaches in combating various forms of cancers.
Jared Kelly's Experience and Vision for Oncolytics
Jared Kelly joins Oncolytics with an impressive background in the biotechnology realm. His previous achievements include a crucial role in facilitating the sale of Ambrx Biopharma to Johnson & Johnson for a substantial $2 billion. With extensive experience in mergers and acquisitions, he has provided invaluable strategic guidance to numerous groundbreaking biotech firms at prestigious law firms such as Lowenstein Sandler LLP and Kirkland & Ellis LLP. Mr. Kelly boasts advanced degrees, including a JD and LLM from Georgetown Law.
Board Chair's Confidence in Kelly's Appointment
Wayne Pisano, Chair of Oncolytics' Board of Directors and outgoing Interim CEO, expressed strong support for Mr. Kelly's new role. He remarked that Kelly’s insights align seamlessly with the groundbreaking clinical data generated by pelareorep. Pisano emphasized that Kelly's demonstrated capability in progressing clinical program development and securing financing will significantly amplify Oncolytics' potential, benefitting patients and investors alike.
Kelly's Commitment to Accelerate Development of Pelareorep
Mr. Kelly expressed enthusiasm about the remarkable clinical findings associated with pelareorep, indicating its transformative role as a foundational immunotherapy for various unmet cancer indications. He highlighted its efficacy in fostering robust immune responses in challenging tumors, showcasing its potential to elevate patient survival rates, particularly where options have been historically limited. With a renewed focus on clinical strategies, Kelly aims to steer pelareorep towards effective partnerships and fortify its market position.
Clinical Advancements with Pelareorep
Pelareorep stands out as an intravenously-administered immunotherapeutic agent having received Fast Track designation by the FDA for promising applications in treating metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC). In clinical trials, pelareorep demonstrated impressive outcomes, achieving over a 60% objective response rate among evaluable mPDAC patients in recent studies, significantly surpassing historical data benchmarks. Additionally, in mBC trials, patients experienced meaningful survival benefits compared to historical controls.
Strengthening Partnerships for Future Development
The consistent efficacy of pelareorep, especially when combined with multiple therapies and checkpoint inhibitors, sets it apart as a prime candidate for further development through strategic partnerships. By focusing on a comprehensive clinical development plan, the company seeks to leverage pelareorep's favorable safety profile, backed by data from over 1,100 patients across various tumor types.
Kelly's Incentives Aligning with Shareholder Interests
In accordance with NASDAQ Listing Rule 5635(c)(4), Mr. Kelly’s appointment comes with significant stock options, including an initial grant for 2,850,000 shares at an exercise price of CAD$0.57, alongside performance-based incentives tied to exceptional financing objectives. This structured grant is designed to align his goals with long-term shareholder value creation.
About Oncolytics Biotech Inc.
Oncolytics is dedicated to pioneering the development of pelareorep, an innovative cancer immunotherapy that shows promise in various malignancies, including metastatic breast cancer and pancreatic cancer. As it advances towards critical registrational studies, the company is committed to developing combination therapies that harness the strengths of pelareorep, aiming to offer impactful treatment options to patients in need.
Frequently Asked Questions
What is the main role of Jared Kelly at Oncolytics Biotech?
Jared Kelly has been appointed as the Chief Executive Officer to drive the company's strategic direction and enhance development programs for its immunotherapy, pelareorep.
What are the key focuses of Oncolytics Biotech?
Oncolytics Biotech focuses on developing pelareorep for the treatment of various cancers, particularly metastatic breast cancer and pancreatic cancer.
What is pelareorep?
Pelareorep is an intravenously-administered immunotherapeutic agent that has shown promising responses in treating different types of cancer, specifically mPDAC and mBC.
How has pelareorep performed in clinical trials?
In clinical trials, pelareorep achieved significant results, including a greater than 60% objective response rate in mPDAC patients, making it a viable option for further development.
What incentives were provided to Jared Kelly for his role as CEO?
Mr. Kelly's package includes stock options and performance-based incentives, which are designed to align his incentives with the creation of long-term shareholder value.
